The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs

Drug Metabolism and Disposition

Volumn 29, Issue 4 I, 2001, Pages 435-442

  Ramji, J V ^a   Austin, N E ^a   Boyle, G W ^a   Chalker, M H ^a   Duncan, G ^b   Fairless, A J ^a   Hollis, F J ^a   Mcdonnell, D F ^a   Musick, T J ^c   Shardlow, P C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Inveresk Research   (United Kingdom)

^c 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BILE SECRETION; DOG; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG URINE LEVEL; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLIC RATE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT INFECTION; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; DOGS; FLUOROQUINOLONES; INTESTINAL ABSORPTION; MALE; MODELS, ANIMAL; NAPHTHYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS;

EID: 0035062505     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Comparative efficacy of gemifloxacin in a rat model of respiratory tract infection
2. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
3. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and Beagle dogs
4. Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man
5. Physiological parameters in laboratory animals and humans
6. Studies to establish quality control ranges for SB-265805 (LB20304) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods
7. In vitro activity of gemifloxacin against Streptococcus pneumoniae, Moraxella catarrhalis, Legionella pneumophila and Chlamydia, in Abstracts of the 21st International Congress of Chemotherapy
8. In vitro activity of gemifloxacin (SB 265805: LB20304a) against human mycoplasmas
9. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin and other antimicrobial agents against bloodstream isolates of Gram positive cocci
10. International multicenter investigation of LB20204, a new fluoronaphthyridone
11. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
12. Anti-streptococcal activity of SB-265805 (LB20304) a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines
13. A new method to collect bile and access the duodenum in conscious dogs
14. In vitro activity of SB-265805 versus gatifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens, in Abstracts of the 9th European Clinical Microbiology and Infectious Diseases (Abstract 222)
15. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone
16. Metabolism and the fluoroquinolones
17. The metabolic interconversion of O-methylbenzophenone oxime isomers
18. Pharmacokinetics of LB20304, a new fluoroquinolone, in rats and dogs
19. Metabolism of gyrase inhibitors
20. Oxidative deamination
21. Factors affecting metabolism and disposition
22. Identification of the metabolites of roxithromycin in humans